Since December 2019, the SARS-CoV-2 has erupted on a large scale worldwide and spread rapidly. Passive immunization of antibody-related molecules provides opportunities for prevention and treatment of high-risk patients and children. Nanobodies (Nbs) have many strong physical and chemical properties. They can be atomized, administered by inhalation, and can be directly applied to the infected site, with fast onset, high local drug concentration/high bioavailability, and high patient compliance (no needles). It has very attractive potential in the treatment of respiratory viruses. Rapid and low-cost development of Nbs targeting SARS-CoV-2 can quickly be achieved. Nbs against SARS-CoV-2 mutant strains also can be utilized quickly to prevent the virus from escaping. It provides important technical supports for the treatment of the SARS-CoV-2 and has the potential to become an essential medicine in the toolbox against the SARS-CoV-2.
【저자키워드】 SARS-CoV-2, Receptor binding domain, phage display, Neutralizing, nanobodies (VHH), 【초록키워드】 Treatment, passive immunization, antibody, children, Local, virus, Bioavailability, respiratory viruses, Spread, inhalation, Patient, nanobodies, Compliance, Rapid, respiratory, High-risk patients, Mutant strains, mutant strain, chemical properties, Support, Administered, high-risk patient, Prevent, physical, applied, provide, the SARS-CoV-2, 【제목키워드】 Against,